{"nctId":"NCT02131233","briefTitle":"Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)","startDateStruct":{"date":"2014-05-23","type":"ACTUAL"},"conditions":["HIV Infection"],"count":802,"armGroups":[{"label":"Reformulated Raltegravir","type":"EXPERIMENTAL","interventionNames":["Drug: Reformulated Raltegravir","Drug: TRUVADA™","Drug: Placebo to Raltegravir"]},{"label":"Raltegravir","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Raltegravir","Drug: TRUVADA™","Drug: Placebo to Reformulated Raltegravir"]}],"interventions":[{"name":"Reformulated Raltegravir","otherNames":[]},{"name":"Raltegravir","otherNames":[]},{"name":"TRUVADA™","otherNames":[]},{"name":"Placebo to Reformulated Raltegravir","otherNames":[]},{"name":"Placebo to Raltegravir","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-1 positive\n* Naïve to antiretroviral therapy including investigational antiretroviral agents\n* Not of reproductive potential or, if of reproductive potential agrees to 1) true abstinence, or 2) use of an acceptable method of birth control during the study\n\nExclusion Criteria:\n\n* Use of recreational or illicit drugs or has recent history of drug or alcohol abuse or dependence\n* Has been treated for a viral infection other than HIV-1 (such as hepatitis B) with an agent that is active against HIV-1 including but not limited to adefovir, tenofovir, entecavir, emtricitabine, or lamivudine\n* Has documented or known resistance to raltegravir, emtricitabine, and/or tenofovir before the first dose of study drug\n* Has participated in a study with an investigational compound or device within 30 days or anticipates participating in such a study during this study\n* Has used systemic immunosuppressive therapy or immune modulators within 30 days or is anticipated to need them during the study (short courses of corticosteroids are allowed)\n* Requires or is anticipated to require any of the following prohibited medications while in the study: phenobarbital, phenytoin, rifampin, rifabutin, or calcium, magnesium and aluminum containing antacids, such as TUMS™, Maalox™ and Milk of Magnesia™\n* Has significant hypersensitivity or other contraindication to any of the components of the study drugs\n* Has current, active diagnosis of acute hepatitis due to any cause\n* Is pregnant, breastfeeding, or expecting to conceive during the study\n* Female participant expecting to donate eggs or male participant expecting to donate sperm during the study\n* Is or has a family member (spouse or children) who is investigational staff or sponsor staff directly involved in this trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving <40 Copies/mL Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Week 48","description":"From blood samples collected at week 48, HIV-1 RNA levels were determined by the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification (LoQ) of 40 copies/mL. The NC=F approach as defined by FDA \"snapshot\" approach was used as the primary approach to analysis where all missing data were treated as failures regardless of the reason.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"88.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving <40 Copies/mL Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Week 96","description":"From blood samples collected at week 96, HIV-1 RNA levels were determined by the Abbott RealTime HIV-1 Assay, which has a limit of reliable quantification (LoQ) of 40 copies/mL. The NC=F approach as defined by FDA \"snapshot\" approach was used as the primary approach to analysis where all missing data were treated as failures regardless of the reason.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.5","spread":null},{"groupId":"OG001","value":"80.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 48","description":"CD4 cells were counted from blood collected at baseline and week 48, and the change from baseline determined from week 48 minus baseline values.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"232.0","spread":null},{"groupId":"OG001","value":"234.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in CD4 Cell Count at Week 96","description":"CD4 cells were counted from blood collected at baseline and week 96, and the change from baseline determined from week 96 minus baseline values.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"261.6","spread":null},{"groupId":"OG001","value":"262.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Adverse Event (AE) at Week 48","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.2","spread":null},{"groupId":"OG001","value":"88.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an AE After 96 Weeks of Treatment","description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null},{"groupId":"OG001","value":"94.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Drug-Related AE at Week 48","description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. An investigator who is a qualified physician evaluated whether or not an AE was drug-related.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":null},{"groupId":"OG001","value":"27.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Drug-Related AE After 96 Weeks of Treatment","description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. An investigator who is a qualified physician evaluated whether or not an AE was drug-related.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.4","spread":null},{"groupId":"OG001","value":"28.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Serious Adverse Event (SAE) at Week 48","description":"A serious adverse event (SAE) is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"9.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a SAE After 96 Weeks of Treatment","description":"A SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Serious and Drug-Related AE at Week 48","description":"A SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. An investigator who is a qualified physician evaluated whether or not a SAE is drug-related.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Serious and Drug-Related AE After 96 Weeks of Treatment","description":"A SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. An investigator who is a qualified physician evaluated whether or not a SAE is drug-related.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Discontinued From Drug Therapy Due to an AE at Week 48","description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Discontinued From Drug Therapy Due to an AE up to Week 96","description":"An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":51,"n":531},"commonTop":["Headache","Nausea","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis"]}}}